CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity

Journal of Immunotherapy

Volumn 31, Issue 1, 2008, Pages 34-42

  Mangsbo, Sara M ^a   Ninalga, Christina ^a   Essand, Magnus ^a   Loskog, Angelica ^a   Tötterman, Thomas H ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

BCG; CpG ODNs; Experimental bladder cancer; MB49; Memory

Indexed keywords

BCG VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; MEDAC; ANTIBODY; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BLOOD ANALYSIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; IMMUNOCOMPETENT CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REGRESSION; URINALYSIS; ANIMAL; BLADDER TUMOR; BLOOD; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE DEPLETION; NUDE MOUSE; PATHOLOGY; SUBCUTANEOUS TISSUE; SURVIVAL; T LYMPHOCYTE; TUMOR CELL LINE; URINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; BCG VACCINE; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; IMMUNOLOGIC MEMORY; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; OLIGODEOXYRIBONUCLEOTIDES; SUBCUTANEOUS TISSUE; SURVIVAL ANALYSIS; T-LYMPHOCYTES; URINARY BLADDER NEOPLASMS;

EID: 40749103853     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181587d29     Document Type: Article

References (39)

1. Alexandroff AB, Jackson AM, O'Donnell MA, et al. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 1999;353:1689-1694.
2. Amling CL. Diagnosis and management of superficial bladder cancer. Curr Probl Cancer. 2001;25:219-278.
3. Schenk-Braat EA, Bangma CH. Immunotherapy for superficial bladder cancer. Cancer Immunol Immunother. 2004;54:414-423.
4. Kuramoto E, Watanabe N, Iwata D, et al. Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction. Int J Immunopharmacol. 1992;14:773-782.
5. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546-549.
6. Bird AP. CpG islands as gene markers in the vertebrate nucleus. Trends Genet. 1995;3:342-347.
7. Takeshita F, Leifer CA, Gursel I, et al. Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol. 2001;167:3555-3558.
8. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740-745.
9. Hartmann G, Battiany J, Poeck H, et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol. 2003;33:1633-1641.
10. Ninalga C, Loskog A, Klevenfeldt M, et al. CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer. J Immunother. 2005;28:20-27.
11. Hegele A, Dalpke A, Barth P, et al. Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/ MB-49 transitional cell carcinoma model. Anticancer Res. 2004;24: 2225-2230.
12. Hegele A, Dalpke A, Heeg K, et al. Immunostimulatory CpG oligonucleotides reduce tumor burden after intravesical administration in an orthotopic murine bladder cancer model. Tumour Biol. 2005;26:274-280.
13. Ratliff TL, Ritchey JK, Yuan JJ, et al. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 1993;150:1018-1023.
14. Jimenez R, Ramirez R, Carracedo J, et al. Cytometric bead array (CBA) for the measurement of cytokines in urine and plasma of patients undergoing renal rejection. Cytokine. 2005;32:45-50.
15. Loskog A, Dzojic H, Vikman S, et al. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor microenvironment. J Immunol. 2004;172:7200-7205.
16. Yang AS, Monken CE, Lattime EC. Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen. Cancer Res. 2003;63:6956-6961.
17. Yang AS, Lattime EC. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res. 2003;63:2150-2157.
18. Halak BK, Maguire HC Jr, Lattime EC. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res. 1999;59:911-917.
19. Loskog AS, Fransson ME, Totterman TT. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res. 2005;11:8816-8821.
20. Loskog A, Bjorkland A, Brown MP, et al. Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J Urol. 2001;166:1093-1097.
21. Gunther JH, Jurczok A, Wulf T, et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res. 1999;59:2834-2837.
22. Brandau S, Riemensberger J, Jacobsen M, et al. NK cells are essential for effective BCG immunotherapy. Int J Cancer. 2001;92:697-702.
23. Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964-1970.
24. Wittes RC. Immunology of bacille Calmette-Guerin and related topics. Clin Infect Dis. 2000;31:59-63.
25. Suttmann H, Riemensberger J, Bentien G, et al. Neutrophil granulocytes are required for effective bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res. 2006;66:8250-8257.
26. Buhtoiarov IN, Sondel PM, Eickhoff JC, et al. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides. Immunology. 2007;120:412-423.
27. Lonsdorf AS, Kuekrek H, Stern BV, et al. Intratumor CpG- oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol. 2003;171:3941-3946.
28. + T cell survival. J Immunol. 2004;172:6065-6073.
29. Peng SL. Signaling in B cells via Toll-like receptors. Curr Opin Immunol. 2005;17:230-236.
30. Chen L, Arora M, Yarlagadda M, et al. Distinct responses of lung and spleen dendritic cells to the TLR9 agonist CpG oligodeoxynucleotide. J Immunol. 2006;177:2373-2383.
31. Luo Y, Yamada H, Evanoff DP, et al. Role of Th1-stimulating cytokines in bacillus Calmette-Guerin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells. Clin Exp Immunol. 2006;146:181-188.
32. Kawarada Y, Ganss R, Garbi N, et al. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol. 2001;167:5247-5253.
33. Sparwasser T, Vabulas RM, Villmow B, et al. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol. 2000;30:3591-3597.
34. Stern BV, Boehm BO, Tary-Lehmann M. Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity. J Immunol. 2002;168:6099-6105.
35. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487-501.
36. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875-1886.
37. + T-cell pool and the expression of Foxp3 in vivo. Int Immunol. 2004;16:1241-1249.
38. + T cell. Int Immunol. 2007;19:193-201.
39. Loskog A, Ninalga C, Paul-Wetterberg G, et al. Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol. 2007;177:353-358.